Corcept Therapeutics Incorporated (CORT) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-24
Business type: Franchise
How it makes money
It earns revenue by selling Korlym and an authorized generic in the United States to treat patients suffering from hypercortisolism.
It markets Korlym and an authorized generic version for the treatment of patients suffering from hypercortisolism, also known as Cushing's syndrome. Sales representatives call on physicians caring for these patients, supported by a field-based force of medical science liaisons.
Because most individuals suffering from hypercortisolism remain undiagnosed or inadequately treated, revenue depends heavily on the company's ongoing educational programs. These initiatives teach physicians how to screen for the disorder and recognize the role its products can play in patient care.
What protects it: the moat
It relies on patents protecting its selective cortisol modulators, while management asserts that its proprietary compounds and methods hold competitive value.
It has discovered more than 1,000 proprietary cortisol modulators that bind to the glucocorticoid receptor without affinity for the progesterone receptor, thereby avoiding certain adverse side effects. The composition of these selective cortisol modulators and their methods of use are covered by U.S. and foreign patents.
However, management notes that securing, maintaining, and effectively asserting patent protection involves slow, expensive litigation whose outcome remains uncertain and subject to challenge on appeal.
What growth costs
It reinvests in clinical trials and research programs to evaluate its lead compounds as potential treatments for serious disorders.
Its lead compounds are evaluated in clinical trials as potential treatments for hypercortisolism, solid tumors, ALS, and MASH. Clinical drug development is lengthy and expensive, requiring substantial ongoing capital to fund research and development activities alongside commercial operations.
What could damage it
A failure of specialty pharmacy vendors to dispense products in a timely manner could directly disrupt commercial distribution and harm financial results.
Distribution of its products has relied on exclusive specialty pharmacy vendors and distributors to provide logistical support to physicians and patients. If these vendors fail to perform their duties or dispense products in a timely manner, patients may experience delays in receiving medication, leading directly to reduced product revenue and weakened financial results.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.